Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Obinutuzumab and Lenalidomide in Previously Untreated Subjects With Follicular Lymphoma

NCT02871219 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT02871219
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02871219 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Obinutuzumab and Lenalidomide in Previously Untreated Subjects With Follicular Lymphoma
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 2
Overall status
Completed
Start date
December 6, 2016
Completion date
June 26, 2024
Enrollment
96 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ann arbor stage ii grade 1 follicular lymphoma, ann arbor stage ii grade 2 follicular lymphoma, ann arbor stage iii grade 1 follicular lymphoma, ann arbor stage iii grade 2 follicular lymphoma, ann arbor stage iv grade 1 follicular lymphoma, ann arbor stage iv grade 2 follicular lymphoma, bulky disease, fatigue, fever, grade 3a follicular lymphoma, night sweats, splenomegaly, weight loss